Gabapentin
Product Images NDC 42495-556

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42495-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westwood Manufacturing, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6ca04cda-figure-01 (Gabapentin Capsules Usp Goa Goa 1)

Chemical structure diagram of the active ingredient gabapentin, showing a cyclohexane ring attached to amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

FDA Label Image

6ca04cda-figure-02 (Gabapentin Capsules Usp Goa Goa 2)

A line graph showing a comparison of mean pain scores over a 7-week period for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores decreasing over time, with Gabapentin treatments showing significantly lower scores than placebo.*

FDA Label Image

6ca04cda-figure-03 (Gabapentin Capsules Usp Goa Goa 3)

A bar chart comparing the percentage of responders at endpoint for placebo (PBO) and Gabapentin (GBP) at different dosages in two studies. Study 1 shows PBO at 12% and GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance markers are indicated for differences between groups.*

FDA Label Image

6ca04cda-figure-04 (Gabapentin Capsules Usp Goa Goa 4)

A scatter plot chart comparing differences in percent (%) on the y-axis against daily gabapentin dose in milligrams (mg) on the x-axis across three studies labeled Study a, Study b, and Study c. The chart shows data points for doses at approximately 600 mg, 900 mg, 1200 mg, and 1800 mg with different percentage differences for each study at corresponding doses.*

FDA Label Image

6ca04cda-figure-05 (Gabapentin Capsules Usp Goa Goa 5)

A line graph showing mean pain scores over eight weeks comparing placebo and Gabapentin (3600 mg/day). It includes a 4-week dose titration period followed by a 4-week fixed-dose period. Gabapentin consistently shows lower mean pain scores than placebo throughout the study.*

FDA Label Image

6ca04cda-figure-06 (Gabapentin Capsules Usp Goa Goa 6)

Gabapentin 100 mg oral capsule blister packaging by Westwood Manufacturing. The clear blister card contains two capsules visible through the foil backing, each capsule is marked with dosing information. The label includes the product name, strength, and labeler details.*

FDA Label Image

6ca04cda-figure-07 (Gabapentin Capsules Usp Goa Goa 7)

Gabapentin 100 mg capsule bottle label from Westwood Manufacturing. The label features the product name, strength, dosage form as capsules, and other regulatory information. The bottle appears dark with a white and yellow label and a white cap.*

FDA Label Image

6ca04cda-figure-08 (Gabapentin Capsules Usp Goa Goa 8)

Gabapentin 100 mg capsules in a blister pack from Westwood Manufacturing. The white and blue capsules are individually sealed in a clear plastic and foil blister card. Capsules are marked with a code visible in blue ink. The package contains 100 capsules.*

FDA Label Image

Image Description (Snip Gaba)

Label for Gabapentin 300 mg capsules by Westwood Manufacturing. The label states the package contains 30 capsules and includes a barcode, lot number, ID, and expiration date placeholders. Usage and storage instructions reference the insert. The repackager's address and phone number in Richmond, VA, are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.